A Penn Medicine patient with a genetic form of childhood blindness gained vision, which lasted more than a year, after receiving a single injection of an experimental RNA therapy into the eye. Visual function at the eye’s foveal cone photoreceptors improved slowly, reaching a substantial peak near three months after the injection.
Graphic courtesy of Artur V. Cideciyan created with BioRender.com.
Penn Medicine researchers have found that a mutation-specific RNA therapy improved vision with lasting effects
A Penn Medicine patient with a genetic form of childhood blindness gained vision, which lasted more than a year, after receiving a single injection of an experimental RNA therapy into the eye. The clinical trial was conducted by researchers at the Scheie Eye Institute in the Perelman School of Medicine at the University of Pennsylvania. Results of the case, detailed in a paper published today in Nature Medicine, show that the treatment led to marked changes at the fovea, the most important locus of human central vision.
The treatment was designed for patients diagnosed with Leber congenital amaurosis (LCA) — an eye disorder that primarily affects the retina — who have a CEP290 mutation, which is one of the more commonly implicated genes in patients with the disease. Patients with this form of LCA suffer from severe visual impairment, typically beginning in infancy.
“Our results set a new standard of what biological improvements are possible with antisense oligonucleotide therapy in LCA caused by CEP290 mutations,” said co-lead author Artur V. Cideciyan, PhD, a research professor of Ophthalmology. “Importantly, we established a comparator for currently-ongoing gene editing therapies for the same disease, which will allow comparison of the relative merits of two different interventions.”
In an international clinical trial led at Penn Medicine by Cideciyan and Samuel G. Jacobson, MD, PhD, a professor of Ophthalmology, participants received an intraocular injection of an antisense oligonucleotide called sepofarsen. This short RNA molecule works by increasing normal CEP290 protein levels in the eye’s photoreceptors and improving retinal function under day vision conditions.
In a 2019 study published in Nature Medicine, Cideciyan, Jacobson, and collaborators found that injections of sepofarsen repeated every three months resulted in continued vision gains in 10 patients. The eleventh patient, whose treatment was detailed in the latest Nature Medicine paper, received only one injection and was examined over a 15-month period. Prior to treatment, the patient had reduced visual acuity, small visual fields, and no night vision. After the initial dose, the patient decided to forgo the quarterly maintenance doses, because the regular dosing could lead to cataracts.
After a single injection of sepofarsen, more than a dozen measurements of visual function and retinal structure showed large improvements supporting a biological effect from the treatment. A key finding from the case was that this biological effect was relatively slow in uptake. The researchers saw vision improvement after one month, but the patient’s vision reached a peak effect after month two. Most striking, the improvements remained when tested over 15 months after the first and only injection.
According to the researchers, the extended durability of vision improvement was unexpected and provides implications for treating other ciliopathies — the name of the large category of diseases associated with genetic mutations encoding defective proteins, which results in the abnormal function of cilia, a protruding sensory organelle found on cells.
“This work represents a really exciting direction for RNA antisense therapy. It’s been 30 years since there were new drugs using RNA antisense oligonucleotides, even though everybody realized that there was great promise for these treatments,” said Jacobson. “The unexpected stability of the ciliary transition zone noted in the patient prompts reconsideration of dosing schedules for sepofarsen, as well as other cilium-targeted therapies.”
One reason why antisense oligonucleotide has proven successful in treating this rare disease, according to the researchers, is that these tiny RNA molecules are small enough to get into the cell nucleus, but are not cleared very quickly, so they remain long enough to do their work.
“There are now, at least in the eye field, a series of clinical trials using antisense oligonucleotides for different genetic defects spawned by the success of the work in CEP290-associated LCA from Drs. Cideciyan and Jacobson,” said Joan O’Brien, MD, chair of Ophthalmology in the Perelman School of Medicine and director of the Scheie Eye Institute
For future studies, the Penn authors are planning gene-specific therapies for other currently incurable blinding inherited retinal disorders.
Original Article: A Single Injection Reverses Blindness in Patient with Rare Genetic Disorder
More from: Perelman School of Medicine at the University of Pennsylvania
The Latest Updates from Bing News & Google News
Go deeper with Bing News on:
RNA therapy
- Ractigen Therapeutics Announces FDA Approval for RAG-01, a First-in-Class saRNA Therapy for BCG-Unresponsive NMIBC
Ractigen Therapeutics, a leader in the development of small activating RNA (saRNA) therapeutics, announced today that the U.S. Food and Drug Administration (FDA) has approved the company's ...
- Two RNA-binding proteins could contribute to cancer therapy development
Highlighting the differences between the two RNA-binding proteins for the first time and their role in cancer development, researchers hope that their research can provide new avenues for drugs to ...
- Oligonucleotides and mRNA vaccines dominate in strategic alliances for RNA therapies : GlobalData
Global data expert forecast that RNA-therapies hold great promise for combating human diseases such as infectious diseases, cancer, neurodegeneration, metabolic disorders, and rare genetic diseases.
- Cow's milk particles unlock one of medicine’s most challenging puzzles
Cow’s milk contains nanoparticles that can be used to deliver disease-modifying RNA therapy orally, according to a new study. With RNA-based drugs currently only administrable by injection, the ...
- This AI Just Designed a More Precise CRISPR Gene Editor for Human Cells From Scratch
Based on large language models—the tech behind the popular ChatGPT—Profluent's AI designed a new gene editor and put it to work in human cells.
Go deeper with Google Headlines on:
RNA therapy
[google_news title=”” keyword=”RNA therapy” num_posts=”5″ blurb_length=”0″ show_thumb=”left”]
Go deeper with Bing News on:
Cilium-targeted therapies
- Study reveals protein's key role in helping cilium transmit signals to the rest of the cell
The essential role played by a protein in the functioning of cells is revealed in new work from the laboratory of Université de Montréal medical professor Frédéric Charron, holder of the Canada ...
- New Developments in Management of Oral Mucositis in Patients With Head and Neck Cancer or Receiving Targeted Anticancer Therapies
Future studies are needed to characterize the clinical presentation of these lesions and compare the toxicity profiles of mTOR inhibitors, other targeted therapies, and conventional cytotoxic agents.
- Development of Targeted Therapy in Uterine Serous Carcinoma, a Biologically Aggressive Variant of Endometrial Cancer
Molecular markers can aid in diagnosis and in monitoring response to therapy in USC. Multiple potential molecular markers for targeted therapy in USC are being studied. erbB2 is overexpressed in ...
- Targeted therapies outperform hundreds of other drugs in 'priming' lung cancer cells for destruction
Through millions of years of evolutionary refinement, the human body has developed a sophisticated surveillance mechanism—the immune system. This intricate network is constantly scanning the body for ...
- Revolutionizing Cancer Treatment: The Transformative Potential of Oral Chemotherapy/ Oral Targeted Therapy
In the dynamic landscape of cancer treatment, Oral Chemotherapy/ Oral Targeted Therapy has emerged as a transformative innovation, providing patients with a self-administered, convenient ...
Go deeper with Google Headlines on:
Cilium-targeted therapies
[google_news title=”” keyword=”cilium-targeted therapies” num_posts=”5″ blurb_length=”0″ show_thumb=”left”]